GLPwatch
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
NCT01931982 · Completed
Last updated 2026-05-28This clinical trial tests whether a medication called GLP-1 can improve blood flow in the small blood vessels of the heart in adults with type 2 diabetes.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, single-blind treatment study
Participants 20 people
Who can join Ages 25–75 · all sexes
Timeline Started 2013-05 · est. completion 2014-04
Where 1 site · Denmark
What this study is testing ClinicalTrials.gov NCT01931982 ↗
Description as written by the study sponsor.
The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes
Treatments tested
- Victoza Drug
| Main thing measured | Change in coronary flow reserve (CFR) |
|---|---|
| Sponsor | Bispebjerg Hospital |
| Conditions studied | Type 2 Diabetes, Microvascular Dysfunction |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01931982 ↗